Vanda Pharmaceuticals Inc（VNDA）の財務VNDAVanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fanapt, accounting for 57.2% of total sales, equivalent to $29.56M. Other significant revenue streams include Hetlioz and PONVORY. Understanding this composition is critical for investors evaluating how VNDA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Vanda Pharmaceuticals Inc maintains a gross margin of 89.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -126.28%, while the net margin is -123.72%. These profitability ratios, combined with a Return on Equity (ROE) of -77.81%, provide a clear picture of how effectively VNDA converts its operational activities into shareholder value.

In the context of the broader market, VNDA competes directly with industry leaders such as IMRX and PRQR. With a market capitalization of $315.62M, it holds a significant position in the sector. When comparing efficiency, VNDA's gross margin of 89.02% stands against IMRX's N/A and PRQR's 100.00%. Such benchmarking helps identify whether Vanda Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Vanda Pharmaceuticals has shown a gross margin of 89.02% in Q2 2026, indicating strong profitability on sales, but it has reported a net income loss of $62.51 million, raising concerns about its financial health.